Yueh-Sheng Chen1, Weng-Tein Gi2, Tin-Yun Liao3, Meng-Tse Gabriel Lee4, Si-Huei Lee5, Wan-Ting Hsu4, Shy-Shin Chang6,7, Chien-Chang Lee4,8. 1. Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. 2. School of Public Health, Heidelberg University, Heidelberg, Germany. 3. Department of Rehabilitation & Physical Medicine, Kaohsiung Veteran General Hospital, Kaohsiung, Taiwan. 4. Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan. 5. Department of Rehabilitation & Physical Medicine, Taipei Veteran General Hospital, Taipei, Taiwan. 6. Department of Family Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan. 7. Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan. 8. Department of Emergency Medicine & Department of General Medicine, National Taiwan University Hospital Yunlin Branch, Douliou, Taiwan.
Abstract
AIM: Galectin-3 (Gal-3) is a new biomarker for assessing prognosis of heart failure (HF) patients. This systemic review and meta-analysis aims to examine Gal-3's ability in assessing prognosis of HF patients. METHOD: We searched MEDLINE and Embase up to November 2014. Test performance characteristics were summarized using forest plots and hierarchical summary receiver operating characteristic curves. RESULTS: The diagnostic odds ratio of Gal-3 in predicting mortality in chronic HF patients was 2.36 (95% CI: 1.71-3.26) and 2.30 (95% CI: 1.76-3.01) in acute HF patients. CONCLUSION: Elevated levels of Gal-3 are associated with mortality in both acute and chronic HF patients. However, current evidence does not support sole use of Gal-3 for prognosis evaluation of HF patients.
AIM: Galectin-3 (Gal-3) is a new biomarker for assessing prognosis of heart failure (HF) patients. This systemic review and meta-analysis aims to examine Gal-3's ability in assessing prognosis of HF patients. METHOD: We searched MEDLINE and Embase up to November 2014. Test performance characteristics were summarized using forest plots and hierarchical summary receiver operating characteristic curves. RESULTS: The diagnostic odds ratio of Gal-3 in predicting mortality in chronic HF patients was 2.36 (95% CI: 1.71-3.26) and 2.30 (95% CI: 1.76-3.01) in acute HF patients. CONCLUSION: Elevated levels of Gal-3 are associated with mortality in both acute and chronic HF patients. However, current evidence does not support sole use of Gal-3 for prognosis evaluation of HF patients.
Authors: Wouter C Meijers; Antoni Bayes-Genis; Alexandre Mebazaa; Johann Bauersachs; John G F Cleland; Andrew J S Coats; James L Januzzi; Alan S Maisel; Kenneth McDonald; Thomas Mueller; A Mark Richards; Petar Seferovic; Christian Mueller; Rudolf A de Boer Journal: Eur J Heart Fail Date: 2021-10-10 Impact factor: 17.349
Authors: Anand Venkatraman; Peter Callas; Leslie A McClure; Fred Unverzagt; Garima Arora; Virginia Howard; Virginia G Wadley; Mary Cushman; Pankaj Arora Journal: Alzheimers Dement (N Y) Date: 2018-04-26